September 2017

Feature

Special Article

Clinical Pathways to Address the Challenges of Treatment Resistance and Relapse in Multiple Myeloma

09/19/2017

Executive Summary Multiple myeloma (MM) is caused by abnormal plasma cell growth in bone marrow, resulting in bone destruction, marrow failure, and adverse blood cell production. The course of MM is characterized by...

...

09/19/2017

Journal of Clinical Pathways

Research Reports

The Impact of Decreasing Variability in Surgical Care Through a Structured Multi-Disciplinary Thoracic Oncology Program

09/19/2017

Clinton D Protack, MD, PhD

Justin D Blasberg, MD

Jia Liu, MD

Shamini Parameswaran, MD

Daniel J Boffa, MD

Lynn T Tanoue, MD

Frank C Detterbeck, MD

Anthony W Kim, MD, MS, FACS, FCCP

Abstract: In order to identify the impact of decreasing variability in surgical care through a structured multidisciplinary thoracic oncology program (TOP), the researchers observed changes following the...

...

09/19/2017

Journal of Clinical Pathways

Perspectives

Rationale for the Development of Clinical Pathways and an Overview of the Clinical Pathways Office at the Seattle Cancer Care Alliance

09/19/2017

Sanu Jain, BS, MHA

Abstract: The United States health care system continues moving away from an unsustainable fee-for-service payment model to more novel measures of care delivery. Clinical pathways have emerged as one of the...

...

09/19/2017

Journal of Clinical Pathways

Column

Clinical Pathways GPS

Clinical Pathways Guiding Where and When

09/19/2017

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

Clinical pathways most often guide treatment decisions based on a diagnosis, but what about assistance for directing where and when care is most effectively rendered? Improving clinical and financial outcomes...

...

09/19/2017

Journal of Clinical Pathways

Pharma Insights

Are Formulary Exclusion Lists Aligned or Contrary to the Shift to Value-Base Care?

09/19/2017

Andrew Cournoyer, RPh, MBA

Larry Blandford, PharmD—Column Editor

The use of formulary exclusion lists continues to expand, with clear impacts to the perception and use of all related medications. Annual updates to these lists suggest a need for careful evaluation by benefit...

The...

09/19/2017

Journal of Clinical Pathways

Editor's Page

Moving the Clinical Pathways Conversation Forward

09/18/2017

Winston Wong, PharmD, Editor-in-Chief

September brings about many things: the end of summer, the beginning of a new school term, and a march toward the conclusion of another calendar year. For those of us at Journal of Clinical Pathways, September marks...

...

09/18/2017

Journal of Clinical Pathways

Insights

Interview

Personalizing Pathways

09/19/2017

JCP Editors

Seattle Cancer Care Alliance (Seattle, WA) has been a leader in clinical pathways for more than a decade. The treatment center—comprised of clinicians from University of Washington School of Medicine, Fred Hutchinson...

...

09/19/2017

Journal of Clinical Pathways

Interview

Financial Navigators to Address Cancer Cost Concerns

09/19/2017

JCP Editors

The passage of the Patient Protection and Affordable Care Act of 2010 (ACA)1 changed the landscape of insurance coverage in the United States. Prior to the ACA’s passage, patients with chronic diseases and...

The...

09/19/2017

Journal of Clinical Pathways

Department

Research in Review

Reviewing the Latest Research on Value-Based Care, Clinical Pathways, and Precision Medicine

09/18/2017

JCP Editors

High Risk of Preventable and Mitigable Adverse Events in Cancer Care Researchers have identified a significant burden of adverse events across the cancer care continuum, including preventable or mitigable...

High...

09/18/2017

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

September 2017

Feature

Column

Insights

Department

Current Issue

Special Reports

Subscribe

Volume 3

Specialties

Events

Year Round Education

HMP Global Products